PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients

被引：3
|
作者：
Contreras, A.
Herrera, S.
Wang, T.
Mayer, I.
Forero, A.
Nanda, R.
Goetz, M.
Chang, J. C.
Pavlick, A. C.
Fuqua, S. A. W.
Gutierrez, C.
Hilsenbeck, S. G.
Li, M. M.
Osborne, C. K.
Schiff, R.
Rimawi, M. F.
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Vanderbilt Univ, Nashville, TN 37235 USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Mayo Clin, Rochester, MN USA
[6] Methodist Hosp, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-PD1-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD1-2
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer - Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies
    Loibl, S.
    Denkert, C.
    Schneeweis, A.
    Paepke, S.
    Lehmann, A.
    Rezai, M.
    Zahm, D-M
    Sinn, P.
    Khandan, F.
    Eidtmann, H.
    Dohnal, K.
    Huober, J.
    Loi, S.
    Pfitzner, B.
    Fasching, P. A.
    Andre, F.
    Lindner, J.
    Sotiriou, C.
    Guo, S.
    Gade, S.
    Nekljudova, V.
    Untch, M.
    von Minckwitz, G.
    CANCER RESEARCH, 2013, 73
  • [32] PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
    Guarneri, V.
    Dieci, M. V.
    Bisagni, G.
    Brandes, A. A.
    Frassoldati, A.
    Cavanna, L.
    Musolino, A.
    Giotta, F.
    Rimanti, A.
    Garrone, O.
    Bertone, E.
    Cagossi, K.
    Nanni, O.
    Piacentini, F.
    Orvieto, E.
    Curtarello, M.
    Chic, N.
    D'Amico, R.
    Prat, A.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S23 - S23
  • [33] Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy
    Chiu, Joanne W.
    Leung, Roland
    Tang, Vikki
    Cheuk, Wai Yin
    Lo, Jessica
    Kwok, Gin Wai
    Wong, Hilda
    Suen, Dacita
    Cheung, Polly
    Wong, Ting Ting
    Yau, Thomas
    Kwong, Ava
    POSTGRADUATE MEDICAL JOURNAL, 2019, 95 (1121) : 155 - 161
  • [34] Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer
    Yu, Anthony F.
    Singh, Jasmeet C.
    Wang, Rui
    Liu, Jennifer E.
    Eaton, Anne
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2017, 22 (06): : 642 - 647
  • [35] Correlation between HER2 related biomarkers (HER2, p95HER2, HER3, PTEN and PIK3CA) and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer refractory to trastuzumab.
    Nishimura, Reiki
    Toh, Uhi
    Tanaka, Maki
    Saimura, Michiyo
    Okumura, Yasuhiro
    Saito, Tsuyoshi
    Tanaka, Toshihiro
    Teraoka, Megumi
    Shimada, Kazuo
    Katayama, Kazuhisa
    Koga, Toshihiro
    Kurashita, Kaname
    Hasegawa, Satoshi
    Todoroki, Hidekazu
    Ueo, Hiroaki
    Arima, Nobuyuki
    Mitsuyama, Shoshu
    Tamura, Kazuo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy
    Sethunath, Vidyalakshmi
    Hu, Huizhong
    De Angelis, Carmine
    Veeraraghavan, Jamunarani
    Qin, Lanfang
    Rimawi, Motthaffar F.
    Osborne, Kent C.
    Schiff, Rachel
    CANCER RESEARCH, 2018, 78 (04)
  • [37] Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).
    Guarneri, Valentina
    Dieci, Maria Vittoria
    Bisagni, Giancarlo
    Generali, Daniele Giulio
    Cagossi, Katia
    Sarti, Samanta
    Frassoldati, Antonio
    Gianni, Lorenzo
    Cavanna, Luigi
    Pinotti, Graziella
    Musolino, Antonino
    Piacentini, Federico
    Michelotti, Andrea
    Cinieri, Saverio
    Griguolo, Gaia
    Miglietta, Federica
    De Salvo, Gian Luca
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [39] Loss of androgen receptor after neoadjuvant anti-HER2 therapy in patients with locally advanced HER2-positive breast cancer
    Espinosa Fernandez, Jose Rodrigo
    Sahin, Aysegul A.
    Hess, Kenneth R.
    Ramirez Medina, Raul Gerardo
    Cabrera Galeana, Paula Anel
    Espana Ferrufino, Alejandro Javier
    Esparza Arias, Nereida
    Bargallo Rocha, Juan Enrique
    Garcia Gordillo, Jose Antonio
    Lopez Muniz, Gerardo Emmanuel
    Ueno, Naoto T.
    CANCER RESEARCH, 2020, 80 (04)
  • [40] Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?
    Zouein, Joseph
    Noujaim, Charbel
    Kourie, Hampig Raphael
    BIOMARKERS IN MEDICINE, 2021, 15 (09) : 609 - 613
12345